TY - JOUR AB - An interested reader drew to our attention that the above study appeared to contain a high level of overlap with an article by the same authors published in the journal Drug Design, Development and Therapy [Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R and Noordin MI: Antiproliferation effect of imatinib mesylate on MCF7, T‑47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF genes. Drug Des Devel Ther 11: 469‑481, 2017]. Following an internal investigation and also in liaison with the authors, it was established that, although the studies were conducted along broadly similar lines, the papers contained entirely different data involving two different subsets of cell lines; the submission to Drug Des Devel Ther aimed to explore the effects of imatinib mesylate on three different groups, with each group being represented by a cell line, whereas the submission to Int J Mol Med explored the effectiveness of imatinib mesylate in breast cancer cell lines. In spite of this, considering the relatedness of the articles and the fact that the paper to Drug Des Devel Ther was submitted first and published while the Int J Mol Med paper was passing through the peer‑review process, the authors concede that they should have properly referenced their paper submitted to Drug Des Devel Ther in the Int J Mol Med paper. Note that the publishers of Drug Des Devel Ther, with whom we were liaising, agreed with the decision to issue a Corrigendum for this paper that acknowledges the article published in Drug Des Devel Ther. The authors regret their failure to acknowledge the related paper in this instance, and apologize to the readership for this oversight. [the original article was published in International Journal of Molecular Medicine 14: 414‑424, 2018; DOI: 10.3892/ijmm.2018.3590]. AD - Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia Department of Pharmacology and Therapeutics, School of Medicine, Faculty of Health and Medical Sciences,Taylor’s University, 47500 Subang Jaya, Malaysia Faculty of Medicine, Shiraz University of Medical Sciences (SUMS), Shiraz 71348‑14336, Iran Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), 14176‑13151 Tehran, Iran AU - Kadivar,Ali AU - Noordin,Mohamed,Ibrahim AU - Aditya,Arya AU - Kamalidehghan,Behnam AU - Davoudi,Ehsan,Taghizadeh AU - Sedghi,Reihaneh AU - Javar,Hamid,Akbari DA - 2019/05/01 DO - 10.3892/ijmm.2019.4119 EP - 2259 IS - 5 JO - Int J Mol Med KW - imatinib mesylate tyrosine kinase receptor breast cancer cell line cell cycle gene expression quantitative polymerase chain reaction protein expression targeted chemotherapeutic agent PY - 2019 SN - 1107-3756 1791-244X SP - 2259 ST - [Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression T2 - International Journal of Molecular Medicine TI - [Corrigendum] Antiproliferative effects of imatinib mesylate on ZR‑75‑1 and MDA‑MB‑231 cell lines via PDGFR‑β, PDGF‑BB, c‑Kit and SCF expression UR - https://doi.org/10.3892/ijmm.2019.4119 VL - 43 ER -